Document is current

Article History

Received: 17 November 2024

Accepted: 18 December 2024

First Online: 3 January 2025

Declarations

:

: Kinga Kołcz has nothing to disclose. Adam Reich has served as an investigator or participated in advisory boards for AbbVie, Almirall, Alvotech, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dermira, Galderma, Inflarx, Janssen, Kiniksa, Kymab, LEO Pharma, Novartis, Pierre Fabre, Pfizer, Trevi Therapeutics, and UCB; and has received honoraria from Boehringer Ingelheim, Chema Rzeszow, Eli Lilly, LEO Pharma, Novartis, Sandoz, and Takeda. Adam Reich is an Editorial Board member of Dermatology and Therapy. Adam Reich was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Magdalena Żychowska has served as an investigator for AbbVie, Galderma, Inflarx, LEO Pharma and Novartis and has received honoraria from Novartis and Takeda.

: Reviewed and approved by the Bioethics Committee of University of Rzeszow (Decision no 2023/04/0023). The patients in this manuscript have given written informed consent to the publication of their case details.